Oral peptide formulations: SLUP-332, BPC, KPV, BAM-15, Orforglipron.
🔥 Popular
NEW BATCH
COA ✓
Oral peptide formulations represent a significant advancement in delivery convenience for research settings. This category features tablet forms of compounds traditionally administered by injection, including BPC-157 Oral Tablets for gut-targeted research, BAM-15 Tablets (a mitochondrial uncoupler), and Orforglipron - the first oral non-peptide GLP-1 agonist in late-stage clinical trials.
| Product | Type | Mechanism | Per Bottle | Research Focus |
|---|---|---|---|---|
| BPC-157 Oral | Peptide | GF upregulation, cytoprotection | 100 tabs | GI healing, gut protection |
| KPV Oral | Peptide | NF-kB suppression | 100 tabs | Gut inflammation, IBD models |
| BAM-15 | Small molecule | Mitochondrial uncoupling (UCP-independent) | 60 tabs | Energy expenditure, fat oxidation |
| SLUP-332 | Small molecule | UCP1 activator | 100 tabs | Brown fat activation, thermogenesis |
| Orforglipron | Non-peptide GLP-1 | Oral GLP-1R agonist | 100 tabs | Weight management, metabolic |
| SLUP-332/BAM-15 Blend | Combo | Dual thermogenic pathway | 60 tabs | Enhanced energy expenditure |
Oral delivery changes the pharmacokinetic profile compared to subcutaneous injection. For researchers comparing routes of administration:
No reconstitution required - tablets are ready to use. BPC-157's gastric origin means it has natural stability in stomach acid. Oral KPV delivers directly to gut mucosal tissue where its anti-inflammatory effects are most relevant. For injectable BPC-157 vials or KPV vials, see our Healing and Skin categories.
BAM-15, SLUP-332, and Orforglipron are small molecules, not peptides - they survive gastric digestion intact. BAM-15 selectively uncouples mitochondria at complex II without the dangerous hyperthermia associated with DNP. Orforglipron may represent the future of GLP-1 agonist delivery.
